TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14644211

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) lenses (31 Pharmacia/Upjohn 811 B and 25 Domilens Flex 60)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Hydroxyethylmethacrylate/methylmethacrylate (HEMA/MMA) lenses (25 Technomed, Memory Lens)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Silicone lenses (32 Allergan Si40)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Acrylic lenses (25 Storz Hydroview)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Cataract surgery with intraocular lens implantation
Number of subjects: 138
Study: 10929899

Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-operated GORD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Operated GORD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Operated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-operated and operated cases
Number of subjects: 0
Study: 8873108

Group type: EXPERIMENTAL
Intervention: Oral morphine (0.429 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diphenhydramine (control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral morphine (0.214, 0.286, 0.357, and 0.429 mg/kg)
Number of subjects: 45
Study: 1379740

Group type: EXPERIMENTAL
Intervention: Bleomycin/cisplatin before radiotherapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Radical radiotherapy
Number of subjects: 97
Study: 6506360

Group type: EXPERIMENTAL
Intervention: Short-term catheter treatment (1 day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Long-term catheter treatment (14 days)
Number of subjects: 43
Study: 30717778

Group type: EXPERIMENTAL
Intervention: Registry-based RCTs
Number of subjects: 0
Study: 29393194

Group type: COMPARATOR
Intervention: Esomeprazole (EPZ)
Number of subjects: 1835

Group type: COMPARATOR
Intervention: Rabeprazole (RPZ)
Number of subjects: 1835

Group type: EXPERIMENTAL
Intervention: Vonoprazan-based triple therapy
Number of subjects: 1835
Study: 26946726

Group type: EXPERIMENTAL
Intervention: Moxibustion at Guanyuan (CV 4), Shenshu (BL 23), Zusanli (ST 36)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Pidotimod 10 mL orally once a day for 90 days
Number of subjects: 230
Study: 25253679

Group type: EXPERIMENTAL
Intervention: Knowledge of diabetes management during Ramadan (measured by aggregate scores from three knowledge questions)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Willingness to attend a workshop on medication regimen adjustment during Ramadan
Number of subjects: 298
Study: 22694242

Group type: EXPERIMENTAL
Intervention: AccuVein AV300 device
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard insertion technique
Number of subjects: 146
Study: 20179619

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% twice daily
Number of subjects: 30
Study: 17610043

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 16234607

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12039617

Group type: EXPERIMENTAL
Intervention: Levo‐alpha‐acetylmethadol (LAAM) maintenance
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 58
Study: 9579498

Group type: EXPERIMENTAL
Intervention: Morphine (bolus dose of 100 microg/kg, followed by continuous infusion of 30 microg x kg(‐1) x h(‐1))
Number of subjects: 24
Study: 8624293

Group type: COMPARATOR
Intervention: 20 Gy radiotherapy to initially involved fields (RT-arm)
Number of subjects: 288

Group type: COMPARATOR
Intervention: 1 X (COPP + ABVD) chemotherapy (CT-arm)
Number of subjects: 288

Group type: COMPARATOR
Intervention: No consolidation therapy
Number of subjects: 288
Study: 2686291

Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without antibiotic prophylaxis
Number of subjects: 0
Study: 799995

Group type: EXPERIMENTAL
Intervention: halcinonide-neomycin-amphotericin
Number of subjects: 100

Group type: COMPARATOR
Intervention: hydrocortisone-iodochlorhydroxyquin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: halcinonide-neomycin-amphotericin cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: hydrocortisone-iodochlorhydroxyquin cream
Number of subjects: 100
Study: 31102257

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg q4w
Number of subjects: 1647

Group type: COMPARATOR
Intervention: Secukinumab 300 mg q6w
Number of subjects: 1647

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg q2w
Number of subjects: 1647
Study: 30417232

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26883438

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous infusion of ponesimod over 3 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg oral administration of ponesimod
Number of subjects: 0
Study: 25791231

Group type: EXPERIMENTAL
Intervention: Monophasic pulsed current (MPC)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MPC coupled with plantar fascia‐specific stretching exercises (SE)
Number of subjects: 44
Study: 24705568

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy and/or contingency management (12-week randomized controlled trial)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy-comparison group (N=20)
Number of subjects: 20
Study: 21482619

Group type: EXPERIMENTAL
Intervention: Interactive CD-ROM-based smoking prevention/cessation curriculum (project ASPIRE)
Number of subjects: 1093
Study: 18486273

Group type: EXPERIMENTAL
Intervention: Weekly vinorelbine chemotherapy (30 mg/m² for 6 weeks)
Number of subjects: 63
Study: 17728357

Group type: EXPERIMENTAL
Intervention: High-dose rhEPO (48,000 IU)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-dose rhEPO (8000 IU)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Drug-naïve Parkinson patients (48,000 IU)
Number of subjects: 8
Study: 15510804

Group type: EXPERIMENTAL
Intervention: Herbal pairs
Number of subjects: 98

Group type: COMPARATOR
Intervention: Banxia Xiexin Tang (Pinellia Decoction for Purging the Stomach‐fire)
Number of subjects: 98
Study: 11589674

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (Andropatch 2.5 mg patches, 1-2 patches per day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 35
Study: 9400916

Group type: EXPERIMENTAL
Intervention: Lispro human insulin (2.0 mU kg(‐1) min(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Human soluble insulin (HS) (2.0 mU kg(‐1) min(‐1))
Number of subjects: 16
Study: 7950410

Group type: EXPERIMENTAL
Intervention: Hyperosmolar agent (glucose solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine challenge in house dust mite-sensitive subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 0
Study: 3298379

Group type: EXPERIMENTAL
Intervention: 4 mg azelastine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 8 mg azelastine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 16 mg azelastine
Number of subjects: 34
Study: 30053681

Group type: EXPERIMENTAL
Intervention: Acupressure wristband applied to the P6 acupoint
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo wristband (without cap)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 111
Study: 27768797

Group type: EXPERIMENTAL
Intervention: IOP-reducing therapy
Number of subjects: 255

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 255
Study: 24108409

Group type: EXPERIMENTAL
Intervention: vestipitant (GW597599) 15 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: alprazolam 0.75 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: vofopitant (GR205171) 25 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 22594907

Group type: EXPERIMENTAL
Intervention: Bisoprolol/hydrochlorothiazide 5/6.25 mg (R)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/160 mg (E)
Number of subjects: 180
Study: 20706173

Group type: EXPERIMENTAL
Intervention: Fluorescein angiography (FA)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Control group (nonstudy eyes)
Number of subjects: 526
Study: 17436336

Group type: EXPERIMENTAL
Intervention: Test formulation T
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation R
Number of subjects: 0
Study: 15872125

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron plus placebo (group H-O)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron plus 8 mg dexamethasone (group H-OD)
Number of subjects: 460

Group type: COMPARATOR
Intervention: None (group L)
Number of subjects: 460
Study: 12373420

Group type: EXPERIMENTAL
Intervention: 7.5 mg delta(9)-THC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 15 mg delta(9)-THC
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7618731

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine 0.125% with epinephrine 1/200,000 (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (bupivacaine and saline)
Number of subjects: 40
Study: 2650578

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg tid orally)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Pentoxifylline and Acenocoumarol (combined treatment)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 333952

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31116270

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) using 20 ml of 0.25% levobupivacaine (ACB-L group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Periarticular infiltration using 40 ml (0.125 mg) of levobupivacaine (PAI-L group)
Number of subjects: 79
Study: 28045766

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 147

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 147
Study: 26677826

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposure (IHE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normoxic control (CON)
Number of subjects: 14
Study: 23244247

Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg/day for 7 days/month followed by Lactobacillus casei for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antibiotic followed by short chain fructo-oligosaccharides
Number of subjects: 40
Study: 21312349

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study: 19747021

Group type: EXPERIMENTAL
Intervention: Managed care disease management program (2006)
Number of subjects: 2906

Group type: EXPERIMENTAL
Intervention: Continuous enrollment in health plan (2006)
Number of subjects: 2906
Study: 16179396

Group type: EXPERIMENTAL
Intervention: LHTL (n = 5) - 14 h/day in hypoxia (6 nights at 2,500 m and 12 nights at 3,000 m)
Number of subjects: 11

Group type: COMPARATOR
Intervention: CON (n = 6) - slept in normoxia (1,200 m)
Number of subjects: 11
Study: 14569399

Group type: EXPERIMENTAL
Intervention: Ultrasonographic muscle thickness (MT) measurements
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Multiple regression equations using MT and limb length
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ultrasonographic MT measurement combined with limb length
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Simple equation using MT only
Number of subjects: 27
Study: 11412292

Group type: EXPERIMENTAL
Intervention: Piritramide
Number of subjects: 92

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 92
Study: 9737127

Group type: EXPERIMENTAL
Intervention: Umbilical vein injection of 20 units of oxytocin diluted to 20 ml with normal saline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline 20 ml
Number of subjects: 50
Study: 8062355

Group type: EXPERIMENTAL
Intervention: Acetaminophen 400 mg-codeine 25 mg combination (ACC)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg (A)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 198
Study: 2522062

Group type: EXPERIMENTAL
Intervention: Intranasal leuprolide 1.6 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Danazol 800 mg/day
Number of subjects: 0
Study: 30617950

Group type: EXPERIMENTAL
Intervention: Synbiotics (15 g of prebiotics, 5 g of probiotic powder containing Lactobacillus acidophilus T16, Bifidobacterium bifidum BIA‐6, Bifidobacterium lactis BIA‐6, and Bifidobacterium longum LAF‐5)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Probiotics (5 g probiotics with 15 g of maltodextrin as placebo)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (20 g of maltodextrin)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 75
Study: 30634880

Group type: EXPERIMENTAL
Intervention: Local lidocaine spray (LS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Forced coughing (FC)
Number of subjects: 86
Study: 28899222

Group type: EXPERIMENTAL
Intervention: Sotagliflozin (400 mg per day)
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1402
Study: 24902822

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Individual adolescent-focused therapy (AFT)
Number of subjects: 121
Study: 24113197

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 62
Study: 22051208

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg, single oral dose)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 19358862

Group type: EXPERIMENTAL
Intervention: Similar distractors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dissimilar distractors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distractors with the same colour as the target on the previous trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus-driven intertrial priming effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top-down controlled similarity effects
Number of subjects: 0
Study: 16401670

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 360

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 360
Study: 15349687

Group type: EXPERIMENTAL
Intervention: Catechu
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tripterygium hypoglaucum hutch tablet
Number of subjects: 100
Study: 11020002

Group type: EXPERIMENTAL
Intervention: alpha2b interferon (6 MU tiw) plus ribavirin (1000-1200 mg daily) for 12 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: alpha2b interferon (6 MU tiw) plus ribavirin (1000-1200 mg daily) for 6 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: alpha2b interferon (6 MU tiw) plus ribavirin (1000-1200 mg daily)
Number of subjects: 50
Study: 9287068

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser de-epithelialization
Number of subjects: 5

Group type: COMPARATOR
Intervention: Reverse bevel incision (Control)
Number of subjects: 5
Study: 7829282

Group type: EXPERIMENTAL
Intervention: Weekly group therapy session in the aftercare clinic
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Counselor continuity in aftercare clinic
Number of subjects: 100

Group type: COMPARATOR
Intervention: Counselor assigned to inpatient unit
Number of subjects: 100
Study: 3065925

Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanate
Number of subjects: 71

Group type: COMPARATOR
Intervention: amoxycillin
Number of subjects: 71
Study: 31751449

Group type: EXPERIMENTAL
Intervention: Moderately high-protein (MHP) diet (30% proteins, 30% lipids, and 40% carbohydrates)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet (22% lipids, 18% proteins, and 60% carbohydrates)
Number of subjects: 305
Study: 29533729

Group type: EXPERIMENTAL
Intervention: 6-mm dental implants
Number of subjects: 96

Group type: COMPARATOR
Intervention: 10-mm dental implants
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Marginal bone levels
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Implant survival rates
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Upper and lower jaws
Number of subjects: 96
Study: 28348503

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Regional anesthesia with opioid PCA)
Number of subjects: 0
Study: 26222435

Group type: EXPERIMENTAL
Intervention: Crinone vaginal progesterone gel (90 mg/d)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Intramuscularly injected progesterone (40 mg/d)
Number of subjects: 1500
Study: 23743437

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% preservative-free ophthalmic solution
Number of subjects: 597

Group type: COMPARATOR
Intervention: Bimatoprost 0.03% ophthalmic solution (Lumigan)
Number of subjects: 597
Study: 20639714

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (40 mg/kg/day for 3 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine treatments for FTT (Control)
Number of subjects: 120
Study: 18191048

Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 17722305

Group type: EXPERIMENTAL
Intervention: Antivir (test formulation)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Retrovir (reference formulation)
Number of subjects: 28
Study: 14508020

Group type: EXPERIMENTAL
Intervention: Helping others
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Receiving help
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Feeling overwhelmed by others' demands
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Prayer activities, satisfaction with prayer life, positive religious coping, age, female gender, being a church elder
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Frequency of prayer and negative religious coping
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: General health, positive and negative religious coping, asking God for healing
Number of subjects: 2016
Study: 11106311

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.0 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1.0 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9183041

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 8237806

Group type: EXPERIMENTAL
Intervention: Enteric-coated magnesium chloride (15.8 mmol magnesium per day)
Number of subjects: 21
Study: 3752618

Group type: EXPERIMENTAL
Intervention: Standardized aluminum hydroxide‐bound dog dander and hair extract
Number of subjects: 27

Group type: COMPARATOR
Intervention: Histamine-placebo
Number of subjects: 27
Study: 30243812

Group type: EXPERIMENTAL
Intervention: Patient-centered, low literacy intervention promoting diabetes self-care including the ACP Diabetes Guide, brief counseling strategy, and training module for health coaches.
Number of subjects: 0
Study: 27127913

Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 20
Study: 24268595

Group type: EXPERIMENTAL
Intervention: Early intervention in a specialised outpatient mood disorder clinic
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 158
Study: 23253957

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Leukapheresis
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Central venous catheter
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control
Number of subjects: 512
Study: 20389141

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 100
Study: 18241756

Group type: EXPERIMENTAL
Intervention: Heparin-bonded expanded polytetrafluoroethylene (ePTFE) graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Gore‐Tex Thin Walled Stretch Vascular Graft
Number of subjects: 20
Study: 16902573

Group type: EXPERIMENTAL
Intervention: Educational material by post and an academic detailing visit by a trained pharmacist (intervention group)
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Educational material by post (guideline group)
Number of subjects: 1497

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1497
Study: 14600112

Group type: EXPERIMENTAL
Intervention: Dislike of school
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Socioeconomic disadvantage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparable knowledge to those liking school
Number of subjects: 0
Study: 10658740

Group type: EXPERIMENTAL
Intervention: Electron beam CT
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Helical CT with pitch of 2
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Single-slice CT without prospective ECG triggering
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Single-slice CT with prospective ECG triggering
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional CT (all modes)
Number of subjects: 160
Study: 8653499

Group type: EXPERIMENTAL
Intervention: 10% polyacrylic acid cleaning for 10-15 seconds
Number of subjects: 137

Group type: COMPARATOR
Intervention: Water rinsing with copious amounts of water
Number of subjects: 137
Study: 1621794

Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises; Duration: 6 weeks; Self-help program
Number of subjects: 10
Study: 6336824

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (pure oxygen)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment (10% oxygen and 90% nitrogen)
Number of subjects: 40
Study: 30887581

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 36
Study: 29571842

Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 3288

Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 3288